Biotech Values

[DewDiligence]

Addendum on Senate biogeneric bill:

1. I expect a shorter exclusivity period than 12 years in the final House/Senate compromise if the exclusivity applies to marketing per se.

2. The exclusivity period may be made to apply to clinical data rather than to marketing, which would allow a FoB company to circumvent the exclusivity period by running its own (abbreviated) clinical program.